KAPANYSEPharmaceutical PreparationsFiscal year ends December 31
Kairos Pharma, LTD.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.57−0.03 (-5.19%)
Close on Oct 19, 2026
- Market cap
- $12.21M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$7.5497 (−92.98%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Split
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $12.21M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 2.91
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$5.81M
- EPS, diluted
- -$0.28
- Book value per share
- $0.20
- Diluted shares
- 21M
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Operating income
-$5.96M
Net income
-$5.81M
EPS, diluted
-$0.28
Reported periodTrailing twelve months